BR112022003464A2 - Composição farmacêutica - Google Patents

Composição farmacêutica

Info

Publication number
BR112022003464A2
BR112022003464A2 BR112022003464A BR112022003464A BR112022003464A2 BR 112022003464 A2 BR112022003464 A2 BR 112022003464A2 BR 112022003464 A BR112022003464 A BR 112022003464A BR 112022003464 A BR112022003464 A BR 112022003464A BR 112022003464 A2 BR112022003464 A2 BR 112022003464A2
Authority
BR
Brazil
Prior art keywords
sulfate
pharmaceutical composition
chondroitin
nasal
reducing agent
Prior art date
Application number
BR112022003464A
Other languages
English (en)
Portuguese (pt)
Inventor
Hideki Watanabe
Kanako Yoshida
Koki FUJIKAWA
Shigeharu Fujieda
Tetsuji Takabayashi
Original Assignee
Maruho Kk
Univ Fukui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maruho Kk, Univ Fukui filed Critical Maruho Kk
Publication of BR112022003464A2 publication Critical patent/BR112022003464A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/736Glucomannans or galactomannans, e.g. locust bean gum, guar gum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
BR112022003464A 2019-09-20 2020-09-18 Composição farmacêutica BR112022003464A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019170955 2019-09-20
PCT/JP2020/035438 WO2021054440A1 (ja) 2019-09-20 2020-09-18 医薬組成物

Publications (1)

Publication Number Publication Date
BR112022003464A2 true BR112022003464A2 (pt) 2022-05-24

Family

ID=74883058

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003464A BR112022003464A2 (pt) 2019-09-20 2020-09-18 Composição farmacêutica

Country Status (10)

Country Link
US (1) US20220347093A1 (https=)
EP (1) EP4032535A4 (https=)
JP (1) JP7313019B2 (https=)
CN (3) CN114650828B (https=)
AU (1) AU2020349263B2 (https=)
BR (1) BR112022003464A2 (https=)
CA (1) CA3154360C (https=)
MY (1) MY206715A (https=)
PH (1) PH12022550661A1 (https=)
WO (1) WO2021054440A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3144752A1 (fr) * 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497209B2 (ja) 1993-08-24 2004-02-16 生化学工業株式会社 硫酸化糖の脱硫酸化方法
JP3512277B2 (ja) 1995-10-05 2004-03-29 有限会社ジーオーメディカルサービス 鼻茸治療・予防剤
JPH10203988A (ja) 1997-01-27 1998-08-04 Meiji Milk Prod Co Ltd 鼻茸および鼻粘膜の浮腫性病変の治療剤
JPH11335288A (ja) * 1998-05-20 1999-12-07 Maruho Co Ltd アレルギー性疾患の予防または治療薬
WO2000069917A1 (fr) * 1999-05-18 2000-11-23 Maruho Kabushikikaisha Compositions medicinales destinees a inhiber le systeme kallikreine-kinine ou la phospholipase a¿2?
EP1922076A4 (en) 2005-08-03 2013-01-23 Morria Biopharmaceuticals USE OF LIPID CONJUGATES IN CYSTIC FIBROSIS AND ITS APPLICATIONS
US20140005115A1 (en) * 2005-11-17 2014-01-02 Yissum Research Development Company Lipid conjugates in the treatment of bronchitis
US8859524B2 (en) * 2005-11-17 2014-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Lipid conjugates in the treatment of chronic rhinosinusitis
CA2790682C (en) 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
JP6637587B2 (ja) * 2015-08-04 2020-01-29 ズートツッカー アーゲー 副鼻腔炎に対するイヌリンの予防的使用

Also Published As

Publication number Publication date
EP4032535A1 (en) 2022-07-27
CN114650828A (zh) 2022-06-21
CA3154360C (en) 2024-01-23
WO2021054440A1 (ja) 2021-03-25
AU2020349263B2 (en) 2023-08-17
CA3154360A1 (en) 2021-03-25
CN118976045A (zh) 2024-11-19
CN118416094A (zh) 2024-08-02
JPWO2021054440A1 (https=) 2021-03-25
US20220347093A1 (en) 2022-11-03
MY206715A (en) 2025-01-03
EP4032535A4 (en) 2023-10-25
JP7313019B2 (ja) 2023-07-24
AU2020349263A1 (en) 2022-04-14
PH12022550661A1 (en) 2023-03-27
CN114650828B (zh) 2024-08-06

Similar Documents

Publication Publication Date Title
Jiang et al. Chitosan as a biomaterial: structure, properties, and applications in tissue engineering and drug delivery
EP2540284A3 (en) Compositions and methods for stabilized polysaccaride formulations
Watterson et al. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
BR112015013774A2 (pt) membrana de hidrogel para prevenção de adesão
JP2011518838A5 (https=)
Johal et al. Viscosupplementation in knee osteoarthritis: evidence revisited
MY198582A (en) Pentosan polysulfate, pharmaceutical composition, and anticoagulant
JP2011522879A5 (https=)
BR112021020302A2 (pt) Composição, e método de tratamento de um sujeito com câncer
BR112015019575A2 (pt) polissacarídeo solúvel em água livre de amido, alimento, ingrediente de alimento, ou suplemento alimentício e método para melhorar a palatabilidade de um polissacarídeo solúvel em água livre de amido
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
Rivera Single intra-articular injection of high molecular weight hyaluronic acid for hip osteoarthritis
NZ603479A (en) Chitosan composition
PT3740191T (pt) Composições oftálmicas compreendendo bilastina, uma beta-ciclodextrina e pelo menos um agente gelificante
BR112018002466A2 (pt) proteção de conteúdo aplicado em hardware para unidades de processamento gráfico
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
BR112022003464A2 (pt) Composição farmacêutica
PE20181294A1 (es) Composiciones y metodos para regeneracion de disco degenerativo
MX2019009711A (es) Mejoras en o con respecto a compuestos organicos.
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.
BR112015022243A2 (pt) dihidroxipropil celulose etilsulfonada reticulada
FI3730521T3 (fi) Pentosaanipolysulfaatti ja pentosaanipolysulfaattia sisältävä lääke
EA032372B1 (ru) Комбинация гликозаминогликанов и циклодекстринов
BR112015024462A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doença

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]